[Comment] GLP-1 and amylin receptor multiagonism with amycretin for obesity management
As is now well known, obesity and excess adiposity is a global health issue, burdening people with multiple comorbidities such as type 2 diabetes, cardiovascular disease, musculoskeletal diseases, cancer, and sleep apnoea.1 The treatment of obesity and its comorbidities has been revolutionised in the past 5–10 years with the introduction of GLP-1 receptor monoagonists such as semaglutide and, more recently, the GLP-1 and glucose-dependent insulinotropic peptide receptor multiagonist tirzepatide.
As is now well known, obesity and excess adiposity is a global health issue, burdening people with multiple comorbidities such as type 2 diabetes, cardiovascular disease, musculoskeletal diseases, cancer, and sleep apnoea.1 The treatment of obesity and its comorbidities has been revolutionised in the past 5–10 years with the introduction of GLP-1 receptor monoagonists such as semaglutide and, more recently, the GLP-1 and glucose-dependent insulinotropic peptide receptor multiagonist tirzepatide.
